


PHARMACEUTICAL 2020

Immune Therapeutics Inc. Rank 273 of 362







Immune Therapeutics Inc. Rank 273 of 362

The relative strengths and weaknesses of Immune Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Immune Therapeutics Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 1,813% points. The greatest weakness of Immune Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 149% points.

The company's Economic Capital Ratio, given in the ranking table, is -421%, being 118% points below the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	4.9
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	13,694
Liabilities, Non-Current	0
Other Assets	0.20
Other Compr. Net Income	0
Other Expenses	133
Other Liabilities	0
Other Net Income	-559
Property and Equipment	0.69
Research and Development	336
Revenues	0
Selling, General and Administrative Expense	2,368

Output Variable	Value in 1000 USD
Assets	5.8
Liabilities	13,694
Expenses	2,838
Stockholders Equity	-13,689
Net Income	-3,397
Comprehensive Net Income	-3,397
Economic Capital Ratio	-421%

